Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1521-1527

  Lurie, Galina ^a   Maskarinec, Gertraud ^a   Kaaks, Rudolf ^b   Stanczyk, Frank Z ^c   Le Marchand, Loïc ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A; CYTOCHROME P450 2B; ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; ENZYME IMMUNOASSAY; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREMENOPAUSE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINALYSIS;

ADULT; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A2; ESTROGENS; FEMALE; GENOTYPE; HUMANS; MENSTRUATION; POLYMORPHISM, GENETIC; PREMENOPAUSE;

EID: 20444408765     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0746     Document Type: Article

References (55)

1. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: rumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
2. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000;21:40-54.
3. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603.
4. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
5. Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86.
6. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997;94:10937-42.
7. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
8. Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 200:95-112.
9. Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996;17:2279-84.
10. Dorgan JF, Longcope C, Stephenson HE Jr, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
11. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997;76:401-5.
12. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
13. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
14. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
15. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
16. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995;768:91-100.
17. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16α-Hydroxylation of estradiol: a possible risk marker for breast cancer. Ann N Y Acad Sci 1986;464:138-51.
18. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
19. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5.
20. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9.
21. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-51.
22. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634-8.
23. Pasagian-Macaulay A, Meilahn EN, Bradlow HL, et al. Urinary markers of estrogen metabolism 2- and 16α-hydroxylation in premenopausal women. Steroids 1996;61:461-7.
24. Telang NT, Suto A, Bradlow HL, Wong GY, Osborne MP. Genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. Recent Prog Horm Res 1993;48:481-8.
25. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
26. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7.
27. Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59:1015-20.
28. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001;61:785-9.
29. Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002;102:172-8.
30. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001;61:3955-60.
31. Marszalek B, Lacinski M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001;15:123-8.
32. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94-101.
33. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
34. Worda C, Sator MO, Schneeberger C, Jantschev T, Ferlitsch K, Huber JC. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum Reprod 2003;18:262-6.
35. Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res 2004;6:R352-65.
36. Maskarinec G, Lurie G, Williams AE, Le Marchand L. An investigation of mammographic density and gene variants in healthy women. Int J Cancer 2004;112:683.
37. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
38. Williams AE, Maskarinec G, Franke AA, Stanczyk FZ. The temporal reliability of serum estrogens, progesterone, gonadotropins, SHBG and urinary estrogen and progesterone metabolites in premenopausal women. BMC Womens Health 2002;2:13.
39. Chen Z, Zheng W, Dunning LM, Anderson KG, Parrish RS, Holtzman JL. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16α-hydroxyestrone in Caucasian women. Steroids 1999;64:856-9.
40. Maskarinec G, Franke AA, Williams AE, et al. Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1736-44.
41. Stram DO, Hankin JH, Wilkens LR, Henderson B, Kolonel LN. Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol 2000;151:358-70.
42. Rinaldi S, Moret CN, Kaaks R, et al. Reproducibility over time of measurements of androgens, estrogens and hydroxy estrogens in urine samples from post-menopausal women. Eur J Epidemiol 2003;18:417-24.
43. Maskarinec G, Franke AA, Williams AE, et al. Effects of a 2-Year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1736-44.
44. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997;57:1063-5.
45. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
46. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-9.
47. Hawaii Department of Business and Economic Development. 2001 State of Hawaii data book: a statistical abstract; 2002 [cited 2002 Sep 19]. Available from: http://www.hawaii.gov/dbedt/db01/index.html.
48. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000;19:1793-819.
49. Hong CC, Tang BK, Rao V, et al. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res 2004;6:R338-51.
50. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and α-tocopherol. Pharmacogenetics 1997;7:11-9.
51. Dawling S, Roodi N, Mernaugh RL, Wang X, Pari FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001;61:6716-22.
52. Scanlon PD, Raymond FA, Weinshilboum RM. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 1979;203:63-5.
53. Westerlind KC, Gibson KJ, Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Steroids 1999;64:233-43.
54. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-48.
55. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983;303:767-70.